바카라 사이트 순위 inks listing deal with major U.S. PBM for Stoboclo-Osenvelt

[by Kang, In Hyo] 바카라 사이트 순위 announced on December 1 that it has successfully secured an early foothold for market share expansion by signing a formulary listing agreement with one of the three major U.S. prescription drug benefit managers (PBMs) for its bone disease treatment, Stoboclo-Osenvelt (denosumab).

Under the agreement, Stoboclo-Osenvelt has not only been added to all public and private insurance formularies managed by the PBM but has also secured ‘preferred drug’ status, allowing for prioritized prescribing. The listing is set to take effect in January 2026, enabling immediate patient reimbursement, and is expected to drive a rapid expansion in prescriptions.

This agreement is particularly significant as Stoboclo-Osenvelt is the only denosumab biosimilar currently available in the U.S. to secure formulary listing. This indicated that the three major PBMs, key decision-makers in the U.S. pharmaceutical market, have given a strong evaluation of Stoboclo-Osenvelt’s product competitiveness, a development expected to positively influence trust in the product and prescription preference among healthcare professionals and patients.

바카라 사이트 순위's U.S. subsidiary also secured a formulary listing agreement with the fifth-largest PBM in the market for Stoboclo-Osenvelt. Under this agreement, Stoboclo-Osenvelt has been designated a preferred drug on all public and private insurance formularies managed by the PBM, with patient reimbursement scheduled to begin in January of next year.

In the United States, where drug prices are high, securing a PBM agreement is virtually essential, as reimbursement is limited to drugs listed on the PBM-managed formularies. Given these market dynamics, the fact that Stoboclo-Osenvelt obtained listings from two of the top five PBMs within just four months of its launch underscores strong market expectations for the product's competitiveness and sales potential from the outset. With these two PBMs included, 바카라 사이트 순위's current U.S. market coverage for Stoboclo-Osenvelt is estimated at roughly 30%.

바카라 사이트 순위 is also moving quickly to finalize formulary listing agreements with two additional major PBMs. The listing agreement for Osenvelt in the private insurance sector under these PBMs has already been completed, leaving only the additional listing agreement for Stoboclo, which is now in its final stages. 바카라 사이트 순위 aims to complete formulary listings with all major U.S. PBMs by swiftly concluding these agreements, along with public insurance listings, thereby securing broad market coverage at an accelerated pace.

Separately from its PBM agreements, Celltrion also plans to target the ‘open market,’ which accounts for approximately 30% of the U.S. denosumab market. The open market is considered a challenging channel for pharmaceutical companies with limited sales capabilities or weaker product competitiveness, as insurers and PBMs exert minimal influence there. Celltrion is demonstrating its competitive strength by directly marketing its anticancer biosimilar, ‘Vegzelma (bevacizumab),’ in the open market, where it achieved a market share of approximately 9% as of October.

"With the rapid completion of Stoboclo-Osenvelt's formulary listing with a major PBM, we have successfully established a strong foundation for delivering high-quality biopharmaceuticals at reasonable prices to patients with bone diseases in the United States. We will actively leverage our established network to quickly secure a leading position in the U.S. bone disease treatment market and work toward achieving earnings growth through expanded product presence," said Thomas Nusbickel, Chief Commercial Officer (CCO) of Celltrion USA.

On the other hand, with the successful launch of its new products, Celltrion is expected to see accelerated sales growth going forward. For ‘Prolia-Xgeva’, the original reference product for Stoboclo-Osenvelt, combined global sales reached around USD 6.599 billion (approximately KRW 9.2 trillion) last year, while U.S. sales alone amounted to about USD 4.392 billion, representing 67% of total revenue.